With over 7,000 medicines and vaccines in development globally for a wide range of diseases, an exciting new wave of medical innovation will play a key role in addressing the challenges faced by patients and by the NHS. Whilst many of these will fail, those that succeed may have a life-changing impact on the lives of patients.
Some of the most impactful new therapies in development are combination therapies for cancer; disease modifying therapies for Alzheimer’s; antibacterial monoclonal antibodies to target antimicrobial resistance; gene therapies against haemophilia; cell therapies against diabetes; and CAR-T cell therapies targeting blood cancers.
In each respective area, these innovative medicines could bring great benefits to patients and their families in terms of survival and quality of life, saving resources in healthcare systems when old treatment methods are taken out of commission and offer benefits to broader society in terms of a healthier workforce.
We won’t rest until CAR-T cell therapies are able to help the body fight back against cancer and potentially replace a lifetime of aggressive chemotherapy treatment.
In CAR-T cell therapy, scientists engineer immune cells to target specific types of blood cancer, using the body's own immune defenses to tackle the cancer. Read more.
Gene therapies offer a potential life change for patients with haemophilia B, and we won’t rest until similar rare diseases can be relieved or even cured.
Haemophilia B is a rare, severe, blood disorder that affects patients from birth. A faulty gene means the body cannot produce the protein Factor IX, which is needed for blood clotting. Read more.
Combining cancer treatments increases their power, helping people live healthier lives; we won’t rest until NSCLC can be kept under control or even cured.
Combinations may include immunotherapies, which improve the patient’s immune response, and targeted therapies, which destroy the cancer cells or prevent them from spreading. Read more.
We won’t rest until cell therapy can replace a lifetime of continuous insulin therapy for patients with diabetes.
Cell therapy involves injecting or inserting living cells into a patient to treat the cause of their disease. The new cells take over the function of the faulty cells, tackling the disease and restoring health. Read more.
We won't rest until antibacterial monoclonal antibodies can slow antibiotic resistance and fight bacterial infections.
Antibacterial resistance is growing, and not enough antibiotics are being produced to tackle the problem. Without action, we will return to the pre-antibiotic era. Read more.